Activation of guanylate cyclase by E. coli heat-stable enterotoxin (STa) Modulation by NAD and pertussis toxin by Epstein, Susan A. et al.
Volume 203, number 1 FEBS 3815 July 1986 
Activation of guanylate cyclase by E. coli heat-stable 
enterotoxin (STa) 
Modulation by NAD and pertussis toxin 
Susan A. Epstein, Ralph A. Giannella+ and Harvey J. Brandwein* 
Department qf Pharmacological Sciences, Health Sciences Center, SUNY Stony Brook, Stony Brook, NY II 794, +Division 
of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 and *Genetic Diagnostics 
Corporation, 160 Community Drive, Great Neck, NY 11021, USA 
Received 15 May 1986 
The heat-stable enterotoxin (STa) of E. coli activates intestinal guanylate cyclase and leads to increased 
cGMP levels by an as yet undetermined mechanism. In comparing this cGMP system to other known toxin- 
mediated alterations in CAMP metabolism, we observed that pertussis toxin caused lower levels of intestinal 
cGMP synthesis in response to purified STa. Another participant in ADP-ribosylation reactions, NAD, en- 
hanced the ability of STa to activate guanylate cyclase, yet had no effect on basal enzyme activity. Niacin- 
amide and isoniacinamide also had no effect on basal activity, but attenuated the STa activation. These 
results are discussed in relation to current models of hormone/toxin-sensitive adenylate cyclase, and may 
suggest an involvement of guanine-nucleotide-binding proteins in intestinal cGMP metabolism. 




Enterotoxigenic strains of E. coli produce pep- 
tide toxins which alter intestinal water balance and 
lead to acute diarrhea1 illnesses in humans and 
many animals [l-3]. A large (85-90 kDa), heat- 
labile toxin (LT) has been well described, and 
shares many structural and functional homologies 
with cholera toxin, including the ability to ADP- 
ribosylate and irreversibly activate intestinal 
adenylate cyclase [4,5]. Another class of E. coli 
toxins are low&&, heat-stable toxins (STs) which 
also cause secretory diarrhea [6,7]. Within these 
STs, there now appear to be two types, STa and 
STb. STb has only been observed in pigs and 
calves, and has not yet been well characterized [S]. 
STa, on the other hand, has been purified to 
homogeneity, and is known to be composed of 
either 18 or 19 amino acids [9- 111. STa has been 
* To whom correspondence should be addressed 
observed to alter dramatically cGMP metabolism 
via the activation of intestinal guanylate cyclase 
[12,13], followed by a blockade of inward ion 
transport and subsequent secretion of water into 
the intestinal lumen [14]. Exogenously added 
cGMP analogues are also capable of directly alter- 
ing ion transport and eliciting a secretory response 
both in vivo and in vitro [15,16]. Thus, it is fairly 
evident at this point that STa alters intestinal 
cGMP metabolism which then leads to changes in 
cellular ion transport. What is less clear is the ac- 
tual mechanism whereby STa activates membrane- 
bound guanylate cyclase in the intestine. While a 
number of laboratories have suggested the STa- 
induced liberation of calcium and/or fatty acid 
metabolites as a model for guanylate cyclase ac- 
tivation [ 17-201, there has been little information 
on how the recently described STa receptor [21,22] 
is actually coupled to intestinal guanylate cyclase. 
In wanting to study this coupling process further, 
we have utilized the current models of hormone- 
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and toxin-sensitive adenylate cyclase to develop ex- 
perimental models. Here, we present evidence that 
STa activation of intestinal guanylate cyclase can 
be modulated by NAD and pertussis toxin, and we 
suggest hat intestinal cGMP metabolism may be 
influenced by guanine-nucieotide-binding pro- 
teins. 
2. MATERIALS AND METHODS 
The heat-stable nterotoxin (STa) of human E. 
co/i strain 18d was purified to homogeneity using 
AmberIite XAD, DEAE-Sephacel and Sephadex 
G-25 chromatography as described [ 111, Purified 
pertussis toxin (PT) was purchased from List 
Laboratories, and was activated just before use as 
described by Katada and Ui [23]. 
Intestinal villous cells were prepared from 
150-200 g female Sprague-Dawley rats by the 
method of Gianella et al. [21]. Washed villous cells 
were suspended in 10 mM Tris-HCI (pH 8), 1 mM 
EDTA, 1 mM DTT, 0.25 M sucrose, and 
homogenized with lo- 15 strokes in a glass Dounce 
homogenizer. For some experiments membranes 
were prepared from homogenates by centrifuga- 
tion at 105000 x g for 60 min at 4°C. 
Homogenates or membranes were adjusted to a 
protein concentration of 5 mg/ml in homogeniza- 
tion buffer, and either used immediately or frozen 
at -70°C 
Guanylate cyclase assays were performed in 
120 ~1 reaction mixtures containing lo- 100 fig 
homogenate or membrane protein, 50 mM Tris- 
HCI (pH 7.6), 10 mM theophylline, 7.5 mM 
creatine phosphate, 20 pg creatine phosphokinase 
(200 U/mg), 1 mM GTP and 4 mM MgCl2 [24]. In 
some experiments, STa, PT, NAD or NAD 
analogues were added at the noted concentrations 
and preincubated for 5-10 min at 37°C. Reactions 
were initiated by the addition of Mg-GTP and in- 
cubated for lo-30 min at 37°C. Incubations were 
terminated by the addition of 0.4 ml cold sodium 
acetate buffer (pH 4) followed by boiling for 3 min 
at 95°C. The amount of cGMP formed was deter- 
mined by RIA [25] using a commercially obtained 
cGMP RIA kit (New England Nuclear, Boston). 
Protein was determined by the method of Lowry et 
al. [26]. All other reagents were of the highest 
quality commercially available and were obtained 
from Sigma (St. Louis). 
3. RESULTS 
Several laboratories have previously reported 
the 2-4-fold activation of intestina1 guanylate 
cyclase by E. coli STa [ 12-141. We also observed 
this activation in homogenized intestinat villous 
cells, and table 1 (column A) shows the effects of 
0.01-l .O pg/ml of STa on guanylate cyclase activi- 
ty. We observed a small increase in guanylate 
cyclase activity beginning with an STa concentra- 
tion of 0.05 pg/ml, and a 2.5--3-fold activation of 
the enzyme with saturating levels of STa 
(>0.5 pg/mI). 
Although we and others have consistently 
observed this STa activation of guanylate cyclase, 
it is still unclear as to precisely how this activation 
occurs on the molecular level. In wanting to study 
this question further, we chose to consider the 
possibility that STa might share some functiona 
homology with other bacterial toxins which alter 
intracellular cyclic nucleotide metabolism by well- 
defined mechanisms [23,27,28]. In particular, we 
chose PT, which is produced by Bordetella per- 
tussis [29] and is known to regulate intracellular 
adenylate cyclase activity via ADP-ribosylation of 
Table I 





Guanylate cyclase activity 
(pmol cGMP/mg per 10 min) 
A B 
0 11.3 F 0.2 13.5 k 0.3 
0.01 11.6 z!z 0.1 22.4 4 0.6 
0.05 18.7 rt 0.5 41.3 * 0.3 
0.10 20.6 + 0.2 59.4 4 0.6 
0.50 27.7 k 0.2 71.1 -+ 1.8 
1.0 27.7 ~?r 0.4 70.0 4 3.4 
The indicated concentrations of purified E. cofi STa 
were added to reaction tubes containing 50 pg villous cell 
homogenate protein and al1 other components of the 
guanylate cyclase assay. Reactions were initiated by the 
addition of Mg-GTP substrate, and analyzed for cGMP 
formed by RIA (see section 2). Column B shows the 
results when l.mM NAD was added for 5 min (37’C) 
before the addition of STa and Mg-GTP. Each point 
represents data of at least duplicate determinations, and 
representative of 3 or more experiments 
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a specific guanine-nucleotide-binding protein, G, 
[23,30]. 
Fig.1 shows that the addition of up to 10~8 
purified PT had no effect on basal guanylate 
cyclase, but surprisingly, led to a 50% decrease in 
the STa activation of the enzyme. This PT effect 
was dose-dependent and was observed in a large 
number of experiments in which the PT blockade 
of STa activation varied from 50 to 7.5% de- 
pending on the villous cell preparation and the 
quantity of PT used (not shown). Freshly prepared 
homogenate and membranes were generally more 
sensitive to PT than were frozen preparations. 
Since PT is known to function enzymatically as 
an ADP-ribosyl transferase [23,30], it seemed 
logical to add the other substrate for the ADP- 
ribosylation reaction, NAD, and see if this had any 
additional effect on intestinal guanylate cyclase. 
Fig.2 shows that NAD had no effect on basal ac- 
tivity at any of the concentrations tested, while 
similar amounts of NAD led to marked enhance- 
ment of the STa activation. The NAD effect was 
dose-dependent, and led to &IO-fold increases in 
guanylate cyclase as opposed to the 2-4-fold in- 
creases seen in the absence of NAD. Also, as 
shown in table 1 (column B), the presence of 1 mM 
H +PT +ST +PT 
+ST 
Fig.1. Effect of pertussis toxin on STa activation of 
intestinal guanylate cyclase. 50 Pg villous cell 
homogenate protein was combined with all components 
of the guanylate cyclase assay except for Mg-GTP 
substrate. Assay tubes then received either IOpg 
activated PT or an equivalent volume (10 ~1) of buffer, 
and were preincubated for 10 min at 37°C. Mg-GTP was 
then added to initiate the reaction and the guanylate 
cyclase assay was performed and analyzed as described 
in section 2. Each point represents data of at least 
duplicate determinations, and is representative of 3 or 
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Fig.2. Effect of NAD on basal and STa-activated 
guanylate cyclase. The indicated concentrations of NAD 
were added to reaction tubes containing membrane 
protein and all other components of the guanylate 
cyclase assay (see section 2 and fig.1). Assays were 
performed in the absence (+---a) or presence (@---O) 
of 100 ng STa, and were initiated by the addition of Mg- 
GTP substrate. 
NAD allowed us to demonstrate activation of 
guanylate cyclase with considerably less STa than 
was required in the absence of NAD. Fig.3 shows 
an almost lo-fold activation of intestinal guanylate 
cyclase in response to STa in the presence of 1 mM 
NAD, and in other experiments, the addition of 
10 pg PT also caused a 50% inhibition of the NAD 
enhanced STa effect (not shown). 
In other experiments, we also found that the 
NAD enhancement of STa activation persisted in 
the presence of equimolar amounts of NADH, 
suggesting that the NAD effect was not simply due 
to a change in pyridine nucleotide redox. 
Moreover, the data suggested to us that an NAD 
driven ADP-ribosylation of a cellular protein 
might be modulating the STa effect on cGMP 
metabolism. To test further this idea, we utilized 
niacinamide and isoniacinamide, two known com- 
petitive inhibitors of ADP-ribosylation reactions 
[3 11. Table 2 shows that neither reagent altered 
basal guanylate cyclase, but both were capable of 
markedly decreasing the STa activation of the en- 
zyme indicating an NAD-sensitive step in the 
process. 
4. DISCUSSION 
ADP-ribosylations of membrane-bound regula- 
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100 
H +PT +ST +PT 
+ST 
Fig.3. Effect of pertussis toxin on STa activation of 
intestinal guanylate cyclase in the presence of 1 mM 
NAD. This experiment was performed as described in 
fig. 1, with the exception that 1 mM NAD was added to 
all reaction tubes before initiating the reaction with Mg- 
GTP as described in section 2. 
Table 2 
Effect of niacinamide and isoniacinamide on STa 
activation of guanylate cyclase 
Addition Guanylate cyclase activity 
(pmol cGMP/mg per 10 min) 
- NAD + 1 mM NAD 
None 13.0 * 0.4 11.8 k 0.2 
10 mM niacinamide 11.6 f 0.5 10.0 * 0.5 
10 mM isoniacinamide 11.7 + 0.2 10.5 + 0.4 
STa (1 &g/ml) 30.0 + 1.5 111.5 + 6.1 
STa plus 10 mM 
niacinamide 21.6 + 0.35 80.7 + 4.1 
STa plus 10 mM 
isoniacinamide 21.5 + 0.2 68.0 * 5.0 
Homogenates were prepared from isolated villous cells 
and assayed for guanylate cyclase activity in the presence 
of the noted additions. Reaction conditions and cGMP 
determinations were as described in section 2 
tory proteins are now well documented mecha- 
nisms whereby other bacterial toxins, such as those 
of Vibrio cholerue and B. pertussis are able to alter 
intracellular CAMP levels in infected cells [4,5,23]. 
Both cholera and pertussis toxins are known to 
regulate adenylate cyclase at the level of the 
guanine-nucleotide-binding proteins, G, and Gi, 
which serve as coupling factors between several 
membrane receptors and the catalytic subunit of 
adenylate cyclase [30]. Our current observations 
on the ability of both NAD and PT to modulate 
the STa activation of guanylate cyclase might also 
suggest he involvement of Gi or a related guanine- 
nucleotide-binding protein in intestinal cGMP 
metabolism. Such an involvement of G-proteins 
with cGMP metabolism has already been observed 
in retinal rod outer segments, where the guanine- 
nucleotide-binding protein, transducin, is coupled 
to a light (rhodopsin) activated cGMP-specific 
phosphodiesterase [32,33]. 
It should be noted that in the case of the large, 
polymeric cholera and pertussis toxins, it is the free 
A-subunit of the toxin which is internalized and 
acts as the enzymatic activity responsible for ADP- 
ribosylating the G-proteins [27]. STa, on the other 
hand, is a small (1900 Da) peptide toxin that has 
no endogenous ADP-ribosyltransferase activity, 
and is not thought to be internalized during the 
early stages of its action (unpublished). Thus, if 
STa does lead directly to ADP-ribosylation events, 
it may be doing so by binding to the STa receptor 
[21,22] and then triggering the activation of 
cellular ADP-ribosyltransferases, which have now 
been described in a number of cell types [34-361. 
Subsequent ADP-ribosylation of G-proteins might 
then act to alter guanylate cyclase and/or cGMP 
phosphodiesterase directly, or might act first on a 
sensitive phospholipase activity as has been recent- 
ly suggested [37,38]. Such activation of 
phospholipase A activity would liberate free fatty 
acids and their oxidative metabolites, which are 
known to be potent activators of guanylate cyclase 
in many tissues [39,40], while the effects of 
phospholipase C activation on guanylate cyclase or 
cGMP phosphodiesterase r main unknown. 
Further studies are clearly needed to elucidate 
fully the mechanism of STa-induced intestinal 
secretion. In particular, it is not clear at present 
why PT and NAD cause opposite effects on cGMP 
accumulation. However, we have recently ob- 
served that rat intestine contains at least 3 G- 
proteins (unpublished) and it is possible that we are 
seeing the result of 2 distinct, yet related events. 
Nonetheless, the findings reported here do suggest 
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that at least in the intestine, there may be some 
analogies between the G-protein/CAMP system 
and the less understood cGMP system. In wanting 
to validate further and study these analogies, 
future efforts will be directed towards identifying 
the specific intestinal G-proteins and observing 
how [32PfADP-ribosyIation of these and other 
membrane proteins lead to alterations in intestinal 
cGMP metabolism. 
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